VivaQuant provides software tools for quantitative analysis of ECGs in clinical and preclinical biomedical and drug safety research. Our ECG analysis services group provides turn-key services for evaluation of arrhythmia liability and quantification of arrhythmias and intervals. Products and services are based upon our proprietary MDSPTM technology that eliminates 95% of noise while preserving fidelity*, enabling highly sensitive and accurate measurements from continuous ambulatory ECGs where signal corruption and artifact are often issues.
VivaQuant was founded in February 2009 by Marina Brockway, PhD after she recognized an unmet need to improve the accuracy of information extracted from ambulatory ECGs and render them more readable. Prior to founding VivaQuant, Dr. Brockway had extensive experience with processing physiological signals at the University of Minnesota Physiology Department, where she developed algorithms for processing nerve recordings, and at Guidant (now Boston Scientific CRM), where she developed algorithms for implantable defibrillators and nerve stimulation devices as well as predictive models to improve the care of patients with chronic cardiovascular disease.
VivaQuantTM ECG analysis services are the choice of leading CROs, medical device firms and pharmaceutical companies to provide dependable and accurate reporting of cardiac arrhythmias and intervals from preclinical and clinical ECGs in biomedical research. VivaQuant ECG analysis services leverage VivaQuant's proprietary Rhythm ExpressTM software incorporating patented Multi-Domain Signal Processing (MDSPTM) technology, the new standard for analyzing noisy ECG recordings often encountered in ambulatory research subjects. The efficiency and precision enabled by this unique technology allows us to provide extremely cost-effective services and state-of-the-art accuracy .
Unique Tools -> Differentiated Services
MDSP removes up to 95% of noise without distorting the underlying ECG signal, which facilitates highly accurate detection of ECG beats and associated intervals and arrhythmias. The time required for manual confirmation of results is therefore minimized and we provide a very high beat-to-beat density of intervals, even with relatively poor signal quality. Optional reporting of J to T-peak and T-peak to T-end parameters provides a novel assessment of arrhythmia liability. For studies where arrhythmia liability is of high concern, VivaQuant has partnered with Fossa Consulting, LLC to offer the combined power of QT beat-to-beat and restitution analyses to greatly improve your ability to distinguish between risky and safe drugs (see separate brochure).
Benefits of using VivaQuant services:
Depending on study need, the following arrhythmias can be reported: Atrial Fibrillation, Bradycardia, Pause, SVE Couplet, SVE Run, Tachycardia, VE Bigeminy, VE Couplet, VE Premature, VE Run, AV Block, Junctional Escape, Atrial Flutter. In addition, the following "abnormal" beat types are reported: Ventricular Ectopic (VE), Supraventricular Ectopic (SVE), Late Beats, and Dropped Beats.
Service offerings include:
 M. Brockway, R. Hamlin. Evaluation of an algorithm for highly automated measurements of QT interval. J Pharmacol Toxicol Methods. 2011; 64:16-24.
VivaQuant has not received any reviews.
VivaQuant has not received any endorsements.